Cytocom Inc., a biopharmaceutical company creating immune therapies that focus on immune restoration and homeostasis, has announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology (LJI), a not-for-profit academic institution and a leader in immunology research.   The agreement is directed to research that will support the development of potential new immune-modulating agents targeting toll-like receptors for the treatment of cancer, i...